Year None20232022202120202019201820172016201520132012201020092008 May 25, 2023 NGM Bio to Participate in Upcoming Investor Conferences Learn More → May 8, 2023 NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023 Learn More → May 4, 2023 NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data Learn More → March 1, 2023 NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference Learn More → February 28, 2023 NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results Learn More → January 12, 2023 NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference Learn More → January 9, 2023 NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities Learn More →